Baird Maintains an 'Outperform' on Inhibitex (INHX); Positive Updates on '189 Profile and Balance Sheet

Baird maintains an 'Outperform' on Inhibitex (NASDAQ: INHX) price target raised from $12 to $15.

Baird analyst says, "Continue to recommend purchase following latest positive updates, thesis reinforced: Synergy between 100mg ‘189 and ribavirin is the latest positive datapoint on the profile of INHX's competitive "nuc" and very important with Hepatitis C development moving aggressively into the interferon-free era. New cash into the company extends the runway to ~2 years. We're increasing our price target to $15, with continued upward bias, and continue to view INHX as one of the most attractive assets in the consolidating HCV space."

For an analyst ratings summary and ratings history on Inhibitex click here. For more ratings news on Inhibitex click here.

Shares of Inhibitex closed at $11.40 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
• Deutsche Bank Downgrades Workday (WDAY) to Hold